Table 2.

Change in concomitant ASM use in patients treated with cenobamate between baseline and 6 months

	Baseline (N = 20)	Month 6 (N = 20)	Change from baseline (N = 20)	p-Value**
Number of concomitant ASMs
Mean (SD)	3 (0.8)	2.5 (1)	− 0.6 (0.7)	0.0009
Median (range)	3 (2–5)	2 (1–5)	− 0.5 (− 2 to 0)
Total DDD ratios for concomitant ASMs*
Mean (SD)	3.6 (1.6)	2.6 (1.6)	− 1 (0.8)	< 0.0001
Median (range)	3.6 (0.9–7.1)	2.4 (0.5–6.1)	− 1 (− 3.2 to 0.2)
Drug load for concomitant ASMs
Mean (SD)	1.2 (0.4)	1 (0.4)	− 0.1 (0.3)	0.038
Median (range)	1.2 (0.5–2)	1.1 (0.4–2)	− 0.2 (− 0.5 to 0.8)

ASM antiseizure medication, DDD daily defined dose, SD standard deviation

*Cenobamate is not included in the DDD ratios computation

**Based on paired t-test